Status:
COMPLETED
RAS Blockade at Bedtime Versus on Awakening for Aldosterone Breakthrough
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Objective: To show that the frequency of aldosterone breakthrough is lower when RAS blockers are given at bedtime compared to on awaking, and to analyze the determinants and consequences of aldostero...
Detailed Description
Rational: Serum aldosterone levels may increase despite blockade of the renin angiotensin system (RAS) with angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB). Thi...
Eligibility Criteria
Inclusion
- Chronic kidney disease stage 3 to 4,
- ACEI (captopril, enalapril, or ramipril), and/or ARB (losartan, valsartan, or irbesartan) on awaking for at least three months,
- History of hypertension or proteinuria \> 0,5 g/24h or g/g creatininuria,
- Adult with social security insurance,
- Informed consent signed.
Exclusion
- Office blood pressure ≥ 160/100 mmHg,
- Pathology with life expectancy \< 1 year,
- Anti-aldosterone (spironolactone, eplerenone) or potassium sparing diuretics (modamide, amiloride), or direct renin inhibitor.
Key Trial Info
Start Date :
February 27 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 12 2018
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT01805362
Start Date
February 27 2013
End Date
January 12 2018
Last Update
April 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nephrology, Nice University Hospital
Nice, France, 06000